Views: 74 Publish Time: 2024-12-02
In recent years, probiotics as functional ingredients have attracted much attention, with new varieties and functions emerging, and AKK bacteria have been honored as the “star intestinal bacteria” due to their unique biological properties and wide range of health benefits. With the deepening of scientific research and the continuous advancement of technology, AM06™ AKK Mucinophilus, a strain derived from breast milk of healthy women, provides consumers with more diversified health choices and injects new vitality into the development of the probiotic market.
01
Revolutionary Breakthrough, “Breast Milk Source AM06™ AKK Bacteria” Online
Mucinophilic Akkermansia muciniphila, or AKK bacteria for short, has attracted widespread attention in the industry since it was first isolated from healthy human feces in 2004 by researchers at the Laboratory of Microbiology, Wageningen University, the Netherlands, Muriel Derrien et al. This oval-shaped Gram-negative bacterium is named after its preference for mucin [1, 2]. As a native bacterium of the human gut, AKK bacteria make up only 3-5% of the human microbial community, but their abundance is strongly correlated with a variety of health indicators in the body.
Despite the great potential of AKK bacteria, their source is a cause for concern. The uncomfortable nature of AKK bacteria being derived from human feces and the risk of translocation of live bacteria to infections certainly limits their widespread use in the market. In addition, AKK is an anaerobic bacterium that is highly sensitive to oxygen, and there are concerns about its stability during production, transportation and storage. These challenges make the commercial application of AKK bacteria face great difficulties. Therefore, the development of safer and more stable AKK bacteria has become a pressing issue for companies.
It is against this background that AM06™ AKK Mucinophilic AKK Bacteria was born. As a strain isolated from healthy breast milk, it not only retains all the advantages of AKK bacteria, but also achieves a qualitative leap in terms of safety, stability and tolerability. The latest study published in Microbiology Spectrum 2023 by a domestic technology development team [3], which comprehensively evaluated 31 AKK bacterial isolates from healthy human subjects, showed that the AM06™ strain has significant advantages, such as low toxicity, high genetic stability, and gastric acid and bile salt tolerance.
Image credit: Microbiology spectrum
According to the researchers, breast milk, as the most natural source of nutrition for infants, is rich in probiotics that have irreplaceable functions in the colonization of the infant's intestinal tract and the development of the immune system, and AM06™, as one of the probiotics found in breast milk, is fully guaranteed to be safe and tolerable. At the same time, breast milk-derived strains are more targeted in studies on infants and neonates [3, 4], which implies that AM06™ has a promising future in the field of infant and child health.
02
From scientific research to clinic, the strength of AKK bacterium witnessed
AKK bacteria, as a kind of beneficial intestinal bacteria, has laid a solid foundation for the development of AKK bacteria from the initial scientific research discovery to gene sequencing, to in vitro in vivo experiments and clinical studies, with abundant scientific research results. Researchers have found that the gut microbiota plays a central role in the prevention of non-alcoholic steatohepatitis (NASH) and its progression to hepatocellular carcinoma (HCC). In a study of Akkobacteria for the prevention of NASH-HCC [5], supplementation with Akkobacteria isolated from breast milk (AM06™) was found to significantly improve NASH and effectively stop its progression to HCC using the STAM model. This finding reveals the key role played by Akk bacteria in blocking the NASH-HCC process.
In addition, it increased the number of hepatic CXCR6+ natural killer T (NKT) cells and reduced macrophage infiltration, thereby modulating the immune response. In studies targeting anti-tumor, Akk bacteria were found to be dependent on NKT cells, and in vitro experiments further confirmed that Akk bacteria can promote the killing of liver cancer cells by NKT cells.
Illustration: AKK bacteria and NKT cells, the anti-tumor effect model of trans-intestinal - hepatic axis action in the liver
In addition, AKK bacteria isolated from breast milk (AM06™) were superior to AKK bacteria isolated from feces (AM02) in improving NASH, suggesting that the source of AKK bacteria may influence its effect. Also, administration of AKK bacteria may affect bile acid metabolism, which is critical for NKT cell activation and HCC prevention.
Further studies have found that the benefits of AKK bacteria are not limited to the prevention of NAFLD. Currently AM06™ AKK Mucinophilic AKK Bacteria completed 8 in vivo and in vitro functional validation studies, as well as 2 complete toxicology and strain safety studies, and the related results have been published in authoritative journals, which provide a solid scientific basis for the safety and efficacy of the product. The studies cover a wide range of levels, from gene level, strain level, in vitro cellular experiments to animal experiments, etc., showing that its abundance is negatively correlated with the risk of inflammatory bowel disease, obesity and type 2 diabetes, which reveals its great potential as a “next-generation star probiotic”.
Image source: TECH-INNO Health
03
High inactivation quality for a new standard of health
Image source: Nat Med
In a randomized, double-blind, placebo-controlled trial conducted in Belgium [6], 32 overweight/obese subjects with insulin resistance were randomized to receive different interventions. The results showed that subjects who received the inactivated AKK bacteria intervention demonstrated significant physiological improvements compared to the placebo group. In particular, the inactivated bacteria group showed a 30% increase in insulin sensitivity, significant improvement in lipid levels with a 9% reduction in total cholesterol, a 7.5% reduction in LDL, a 16% reduction in triglycerides, and a significant reduction in intestinal inflammatory markers.
In addition, a study addressing weight and body fat found that subjects in the inactivated group lost an average of 2.3 kilograms, 1.4 kilograms of which was fat, and also experienced a reduction in hip circumference and waist circumference of 2.6 centimeters and 1.6 centimeters, respectively (although the statistical significance of the change in waist circumference did not meet the preset criteria). The study reveals the potential of inactivated AKK bacteria in improving insulin sensitivity, lipid levels and weight loss in overweight/obese subjects, opening up new research directions for future probiotic solutions.
Excitingly, AM06™ AKK Mucinophilic Akemi stands out from the crowd of probiotics by virtue of its inactivated bacterial form, which employs its own PROFORCARE® Heat-InActived Inactivation Technology, which inactivates AKK bacteria at lower temperatures while partially or completely retaining their beneficial effects, and crucially, the outer membrane protein Amuc 1100 remains active after heating, demonstrating unique Key to this is the fact that the outer membrane protein Amuc 1100 remains active even after heating, demonstrating a unique advantage.
-High genetic stability
At the level of genetic material, AM06™ is able to pass on its health properties in a stable manner, ensuring that the optimal probiotic benefits are realized with each generation of the product. This not only enhances the reliability of the product, but also brings continuous health protection to consumers.
-Highly tolerant
Whether it is the strong corrosion of stomach acid or the complex environment in the intestines, AM06™ is able to cope with it, ensuring that the probiotics can reach the intestines and function smoothly. The strong tolerance makes highly inactivated probiotics unique among similar products.
-Long shelf life
In addition, the inactivated probiotic has a long shelf life, good stability, no need for refrigeration and other convenient features, easy to store and transport. Also, as inactivated bacteria, AM06™ is not affected by antibiotics and can be used in conjunction with antibiotics, providing consumers with more flexible use options.
04
Partnering with Taiyi Health to create a healthy future
In the booming development of the global health industry, probiotics, as an important ingredient in maintaining the micro-ecological balance of the human body and promoting health, are increasingly receiving widespread attention. The European Union, the United States, Canada and other countries and regions have introduced a series of regulations to provide policy support for the innovation of new foods and dietary supplements, and second-generation probiotics, such as AKK, have been successfully approved by the regulations of these regions and formally included in the ingredients of new foods or dietary supplements, which has injected new vitality into the market.
In order to ensure the intellectual property rights and market exclusivity of probiotic products, AM06™ AKK Mucinophilic AKK has applied for as many as 21 patents both at home and abroad in the areas of isolation and culture, metabolic diseases, psychiatric disorders, digestive disorders, and oncology, which not only cover the screening, cultivation, extraction, and processing of probiotics, but also go deeper into the application, design, and production of the products, import and export, and supply chain management, laying the foundation for the comprehensive marketization of the products.
Against this background, Taiyi Health, with its profound industry deposits and forward-looking market insights, has actively engaged in the application and market cooperation of the second-generation probiotics represented by AM06™ AKK Mucinophilic Ackermannia in the field of great health. As a leader in the industry, Taiyi Health has an advanced R&D platform and strong production capacity, bringing together a R&D team of senior experts. From the initial conception of the product to the final market launch, the enterprise can provide professional support to ensure that customers can successfully launch probiotic products that meet the market demand and are competitive.
The company understands that only through continuous innovation can we stand invincible in the fierce market competition. Taiyi Health continues to push forward and introduce new concepts, products and solutions to promote the development of AM06™ AKK Mucinophilus Ackermanniae in a variety of niche areas, such as anti-aging, lipid and glucose management, weight management, intestinal health, etc., and to provide precise and effective solutions for all types of consumers. Looking ahead, Taiyi Health will continue to uphold the development concept of “Innovation, Cooperation and Win-Win”, and work hand in hand with domestic and international partners to promote the development of the probiotic industry and create a better future for health.
References:
[1]Geerlings, S.Y., et al., Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How? Microorganisms, 2018. 6(3).
[2] Derrien, M., et al., Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol, 2004. 54(Pt 5): p. 1469-1476.
[3]Safety Evaluation and Probiotic Potency Screening of Akkermansia muciniphila Strains Isolated from Human Feces and Breast Milk.2023-02-14, doi: 10.1128/spectrum.03361-22
[4]Bifidobacterium animalis subsp. lactis Probio-M8 undergoes host adaptive evolution by glcU mutation and translocates to the infant’s gut via oral-/entero-mammary routes through lactation. Microbiome . 2022.11.22
https://www.cn-healthcare.com/articlewm/20221208/content-1479900.html
[5]BIAN X, WU W, YANG L, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice [J]. Frontiers in microbiology, 2019, 10: 2259.
[6]Clara Depommier, Amandine Everard, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019 July 01; 25(7): 1096–1103. doi:10.1038/s41591-019-0495-2.
